Introduction Natural killer (NK) cell–based immunotherapy has emerged as a promising strategy in cancer treatment because of its ability to mediate tumor killing without prior antigen sensitization. However, clinical efficacy in solid tumors has remained limited, largely due to poor tumor infiltration, immune suppression within the tumor microenvironment and uncertainty regarding the most therapeutically effective NK-cell subsets.
Introduction
Natural killer (NK) cell–based immunotherapy has emerged as a promising strategy in cancer treatment because of its ability to mediate tumor killing without prior antigen sensitization. However, clinical efficacy in solid tumors has remained limited, largely due to poor tumor infiltration, immune suppression within the tumor microenvironment and uncertainty regarding the most therapeutically effective NK-cell subsets.
Problem Statement
Conventional ex vivo expanded NK cells often fail to adequately infiltrate and persist within solid epithelial tumors, reducing their therapeutic effectiveness. At the same time, tissue-resident NK (trNK) cells represent a biologically diverse population, with some subsets demonstrating immunosuppressive properties while others appear highly cytotoxic. Identifying and selectively expanding the most effective antitumor trNK population remains a major challenge in adoptive NK-cell therapy.
Summary
This translational study identifies a distinct population of highly cytotoxic tissue-resident NK cells characterized by coexpression of CD39, CD49a and CD103, termed cytotoxic trNK (ctrNK) cells, with potent activity against solid epithelial tumors. Using multiomic characterization, the investigators demonstrated that these ctrNK cells possess enhanced tumor-killing capacity, superior migration into tumor organoids and markedly improved control of solid tumors in vivo compared with conventionally activated peripheral NK cells. Importantly, the enhanced antitumor activity appeared linked not only to cytolytic function but also to improved tissue infiltration and retention within the tumor microenvironment, partly mediated through CD103-associated epithelial adhesion mechanisms. A particularly significant finding was that exposure to epithelial tumor cells during ex vivo expansion could drive differentiation toward this highly cytotoxic tissue-resident phenotype, creating a potentially scalable platform for adoptive immunotherapy. These findings directly address one of the major barriers in solid tumor immunotherapy—the inability of transferred immune cells to effectively penetrate and function within immunosuppressive tumor environments. The study positions ctrNK cells as a promising next-generation cellular therapy platform for solid malignancies and provides an important biologic framework for refining NK-cell engineering and expansion strategies in cancer immunotherapy.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.